Dasatinib in solid tumors

Bibliography

• Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4(6):470-80
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Roh MS, Curley SA, Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993;91(1):53-60
   PubMed Web of Science ®Google Scholar
• Moasser MM, Srethapakdi M, Sachar KS, Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 1999;59(24):6145-52
   PubMed Web of Science ®Google Scholar
• Yezhelyev MV, Koehl G, Guba M, Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004;10(23):8028-36
   PubMed Web of Science ®Google Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6(10):587-95
   PubMed Web of Science ®Google Scholar
• Cartwright CA, Meisler AI, Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 1990;87(2):558-62
   PubMed Web of Science ®Google Scholar
• Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42
   PubMed Web of Science ®Google Scholar
• Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood 1999;93:1-14
   PubMed Web of Science ®Google Scholar
• Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379-86
   PubMed Web of Science ®Google Scholar
• Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small cell lung cancer. Ann Oncol 2008;19:1219-23
   PubMed Web of Science ®Google Scholar
• Bolen JB, Veillette A, Schwartz AM, Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells. Oncogene Res 1987;1(2):149-68
   PubMedGoogle Scholar
• Lutz MP, Esser IB, Flossmann-Kast BB, Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243(2):503-8
   PubMed Web of Science ®Google Scholar
• Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992;52(17):4773-8
   PubMed Web of Science ®Google Scholar
• Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22(4):337-58
   PubMed Web of Science ®Google Scholar
• SPRYCEL® (dasatinib) Tablets Prescribing Information. Bristol-Myers Squibb Company P, NJ. November 2007. Available from: www.sprycel.com/
   Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, Dasatinib induces notable hematologic and cytogenietic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109(6):2303-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109(12):5143-50
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109(10):4143-50
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109(8):3207-13
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinello G, Dasatinib induces rapid hematologic and cytogenetic responses in adults patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110(7):2309-15
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65(20):9185-9
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11(19):6924-32
   PubMed Web of Science ®Google Scholar
• Song L, Morris M, Bagui T, Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66(11):5542-8
   PubMed Web of Science ®Google Scholar
• Trevino JG, Summy JM, Lesslie DP, Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168(3):962-72
   PubMed Web of Science ®Google Scholar
• Dasatinib chemical compound. Available from: http://pubchem.ncbi.nlm.nih.gov
   Google Scholar
• Brave M, Goodman V, Kaminskas E, Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14(2):352-9
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25(9):1035-44
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Durnberger G, Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110(12):4055-63
   PubMed Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23(3):477-85
   PubMed Web of Science ®Google Scholar
• Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009;5(9):616-24
   PubMed Web of Science ®Google Scholar
• Luo FR, Barrett YC, Yang Z, Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008;62(6):1065-74
   PubMed Web of Science ®Google Scholar
• Demetri GD, Lo Russo P, MacPherson IR, Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15(19):6232-40
   PubMed Web of Science ®Google Scholar
• Serrels A, Macpherson IR, Evans TR, Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006;5(12):3014-22
   PubMed Web of Science ®Google Scholar
• Dasatinib (BMS-354825) oncologic drug advisory commitee (ODAC) briefing document. Available from: http://www.fda.gov/
   Google Scholar
• Johnson FM, Agrawal S, Burris H, Phase I, pharmacokinetic and drug interaction study of dasatinib in patients with advanced solid tumors. Cancer 2009. In press
   Google Scholar
• Bergeron A, Rea D, Levy V, Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176(176):814-8
   PubMed Web of Science ®Google Scholar
• Esteve FR, Stoller RG, Josephson A, Phase I trial of cetuximab ( C ) and dasatinib (D) in patients with advanced solid malignancies. 2008 ASCO annual meeting. J Clin Oncol 2008;26 (20s): abstract 14668
   Google Scholar
• Uronis HE, Bullock K, Blobe G, A phase I study of gemcitabine +dasatinib (GD) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. Abstract No. 276. 2009 Gastrointestinal Cancers Symposium, San Francisco, USA, Jan 15-17, 2009
   Google Scholar
• Tan M, Li P, Klos KS, ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 2005;65(5):1858-67
   PubMed Web of Science ®Google Scholar
• Mayer E, Baurain J, Sparano J, Dasatinib in advanced HER2/neu amplified and ER/PR positive breast cancer: phase II study CA 180088. J Clin Oncol 2009;27 (15s): abstract 1011
   Google Scholar
• Kluger HM, Dudek C, McCann L, A phase II trial of dasatinib in advanced melanoma. J Clin Oncol 2009;27(15s): abstract 9010
   PubMed Web of Science ®Google Scholar
• Yu EY, Wilding G, Posadas E, Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15(23):7421-8
   PubMed Web of Science ®Google Scholar
• Johnson FM, Tang H, Tran B, Phase II study of dastinib in non-small cell lung cancer (NSCLC). 2009 ASCO annual meeting. J Clin Oncol 2009;27(Suppl): abstract e19015
   Google Scholar
• Brooks HD, Glisson C, Lu A, Phase II study of dasatinib in the treatment of head ad neck squamous cell carcinoma (HNSCC). 2009 ASCO annual meeting. J Clin Oncol 2009;27(15s): abstract 6022
   PubMed Web of Science ®Google Scholar
• Somlo G, Atzori F, Strauss A, Dastinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): phase I study CA 180004. J Clin Oncol 2009;27(15s): abstract 1012
   PubMed Web of Science ®Google Scholar
• Araujo J, Gallick G, Trudel P, Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180-086). Abstract 177. 2009 Genitourinary Cancer Symposium, Orlando, USA. Feb 26-28, 2009
   Google Scholar
• Haura EB, Tanvetyanon T, Chiappori A, Phase I study of SRC inhibitor dasatinib in combination with erlotinib in advanced non-small cell lung cancer. J Clin Oncol 2009. In press
   Google Scholar
• Kopetz S, Wolff RA, Glover L, Phase I study of Src inhibition with dasatinib in combination with 5-fluoruracil,leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. Abstract No. 325. 2008 Gastrointestinal Cancer Symposium, San Francisco, USA. Jan 15-17, 2009
   Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Clonal expansion of T/NK- cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-405
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, Kim DW, Phase 3 study of dastinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15- month median follow up. Blood 2009;113(25):6322-9
   PubMed Web of Science ®Google Scholar
• Sos ML, Michel K, Zander T, Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009;119(6):1727-40
   Google Scholar
• Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004;6(3):209-14
   PubMed Web of Science ®Google Scholar
• Ceppi P, Papotti M, Monica V, Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 2009;8(11):3066-74
   PubMed Web of Science ®Google Scholar
• Dressman HK, Berchuck A, Chan G, An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25(5):517-25
   PubMed Web of Science ®Google Scholar
• Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 2009;124(1):1-6
   PubMed Web of Science ®Google Scholar
• Zhang XH, Wang Q, Gerald W, Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16(1):67-78
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, O'Brien S, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908-14
   PubMed Web of Science ®Google Scholar